about
Long-term follow-up of thalamic deep brain stimulation for essential tremor - patient satisfaction and mortality.Aggravated stuttering following subthalamic deep brain stimulation in Parkinson's disease--two casesLinkage disequilibrium and association of MAPT H1 in Parkinson diseaseIdentification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations.Surgical site infections after deep brain stimulation surgery: frequency, characteristics and management in a 10-year period.Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease.Fine-mapping and candidate gene investigation within the PARK10 locus.Effective variant detection by targeted deep sequencing of DNA pools: an example from Parkinson's disease.Self-Reported Executive Functioning in Everyday Life in Parkinson's Disease after Three Months of Subthalamic Deep Brain Stimulation.Large-scale assessment of polyglutamine repeat expansions in Parkinson diseaseThe role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease.Targeted high throughput sequencing in hereditary ataxia and spastic paraplegiaCopy number variation in Parkinson's disease.Genetic variability in SNCA and Parkinson's disease.Advances in genetic diagnosis of neurological disorders.The GBA variant E326K is associated with Parkinson's disease and explains a genome-wide association signal.A cumulative genetic risk score predicts progression in Parkinson's disease.Supportive evidence for 11 loci from genome-wide association studies in Parkinson's disease.Personality changes after deep brain stimulation in Parkinson's diseaseCorrection: Targeted high throughput sequencing in hereditary ataxia and spastic paraplegia.Genomewide association, Parkinson disease, and PARK10Parkinsonism, FXTAS, and FMR1 premutations.Variants in the LRRK1 gene and susceptibility to Parkinson's disease in Norway.Clinical features of LRRK2-associated Parkinson's disease in central Norway.Found in transcription: accurate Parkinson's disease classification in peripheral blood.[Malignant hyperthermia--a hereditary and potentially life-threatening condition].Rare variants in dementia genes and Parkinson's disease.Lrrk2 and Lewy body disease.Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian population.Longitudinal assessment of probable rapid eye movement sleep behaviour disorder in Parkinson's disease.Clinical features associated with sleep disturbances in Parkinson's disease.MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's disease.REM sleep behavior disorder in Parkinson's disease--is there a gender difference?Parkinson's disease correlates with promoter methylation in the α-synuclein gene.The Wilson films--MS tremor.Levodopa-responsive parkinsonism in probable extrapontine myelinolysis of the mesencephalon.Insufficient evidence for pathogenicity of SNCA His50Gln (H50Q) in Parkinson's disease.Lrrk2 G2019S substitution in frontotemporal lobar degeneration with ubiquitin-immunoreactive neuronal inclusions.Clinical traits of LRRK2-associated Parkinson's disease in Ireland: a link between familial and idiopathic PD.FMR1 premutations associated with fragile X-associated tremor/ataxia syndrome in multiple system atrophy.
P50
Q33736806-AFB01D94-0360-4053-BF53-8F03E89C6BF9Q33866344-720A55EC-CEA5-4B31-873A-58DA32C24F74Q33910188-798A81E9-AF97-49AB-B794-75705AFDCC6AQ33942173-7BC6E384-85CA-465B-8450-A9FCA50E1E3FQ34047288-B96EEA34-5544-405D-8096-78F795CA8E25Q34267681-0CA750BA-37E2-4C0F-ACB9-AEF23AB539C6Q34325867-4F51EEBF-FFCB-41C0-A8AA-F11CC2447752Q35128698-C57CE2C6-8A22-4B50-B7CB-3B9F0DC4B379Q35808249-53CDA7DF-B8EB-46BB-84E0-0BE431A3063FQ36196950-B1B8FA19-EBB4-447B-8371-D037A9D9D0E6Q36233594-66076EE0-57E6-45F9-985C-DDB7E5E75D4FQ36330076-E78C0826-FFFA-459D-94D0-526E0A1B589AQ37786653-0B294F8C-549E-4CBD-B0BC-ED33BABECCD7Q37907930-9EF1BA7C-5913-4E18-BC3C-52C3F215CB64Q38192694-26C74B53-8D63-4544-8B41-5BDA1AA05863Q38613451-2E901567-D214-4FC6-8C3F-ABAE1B25D44DQ38725615-2957B948-6592-43EC-8E55-4A21472B4342Q39519664-D5A33A71-39E2-4A29-924B-8E2A02F2B25CQ41902373-5DDF5F37-F2A3-4CCB-AB37-B7A9463ABC47Q42375859-6C2ACD27-DAD7-439D-9CD4-9267887DA5E3Q42418561-49AF6B74-D6BE-47EB-8631-E58B23D3A3E4Q43857189-EC40F2F9-34BA-4D05-9897-CBFEE85C3A8EQ44150736-680BC652-0231-4042-A1D6-5D04B3C9A1EAQ44830290-C466BD02-7D52-4185-8E46-DDF313D6496CQ45265937-2C3DE8FB-1103-433C-9F14-24F95957A51EQ46770207-EEE97C9F-D864-4692-AC73-D74A71B2BD52Q46881256-A986A44E-E547-495E-B6CA-159AC7A5649FQ46912096-92511189-9C13-4624-8B1E-755D9413960EQ46943278-F9B04DE9-A0C7-4F54-A439-D4C2CDCFD68DQ47978190-5C27B822-AA5F-4D6A-9351-DEF28F7D99DEQ48094582-50B74C1E-0F73-4AE9-ACEC-C39AAC17427CQ48228472-8BD96FBE-BE7E-4D53-95B9-B3FB63ADC9A4Q48237112-14D300BF-AD4C-4399-8C0C-D4F8B0EA5FF1Q48397887-A1F19946-8509-4CCD-81C5-D6262D246CBAQ48518856-34BF6A9C-0F7B-48F9-81AA-26BA716B9811Q48824378-CD5BBF5B-E7A6-4318-81A7-A115015B4180Q49344513-A89CA5F2-CFCB-436D-8A64-74443749BCFBQ50277647-9444B42E-D5EE-4BB6-BAFB-411B1283156EQ50279567-C66C643D-7621-4753-9273-AF1BEEDE3D24Q50279964-DEA0D471-C984-4281-A3F1-C5E376C61A9A
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Mathias Toft
@ast
Mathias Toft
@en
Mathias Toft
@es
Mathias Toft
@nl
Mathias Toft
@sl
type
label
Mathias Toft
@ast
Mathias Toft
@en
Mathias Toft
@es
Mathias Toft
@nl
Mathias Toft
@sl
prefLabel
Mathias Toft
@ast
Mathias Toft
@en
Mathias Toft
@es
Mathias Toft
@nl
Mathias Toft
@sl
P106
P1153
56485505900
9134165200
P21
P214
2144149296270580670008
P31
P4012
P496
0000-0002-6723-6865
P735
P7859
viaf-2144149296270580670008